QuidelOrtho Corporation shares fell approximately 14% after the Company reported a Q3 revenue shortfall of roughly $618.9 million, representing a year-over-year sales decline of approximately 11.6%–12% that missed Wall Street consensus estimates. Although the Company posted an adjusted earnings per share beat of $0.31 versus expected consensus of about $0.20–$0.21, investors focused on weak top-line performance driven by major segment headwinds. Disclosed pressures included a 45% decline in China revenue due to distributor destocking and pricing changes, a 27% drop in Point-of-Care revenue, and a 39% decline in respiratory revenue. In response, management narrowed full-year revenue expectations and announced an approximately $100 million restructuring program through 2027. Previously, on the Q3 2025 earnings call on November 5, 2025, Chief Executive Officer Brian Blaser stated that "Japan, Asia Pacific and China each grew approximately 5%". Additionally, in a Form 10-Q filing, the Company addressed potential China business impacts by stating, "Based on current information, we believe that any potential business impact would not likely be material to our total annualized revenue," alongside negative operating cash flow of $143.6 million. The investigation concerns whether QuidelOrtho Corporation adequately disclosed operating headwinds, distributor destocking, and segment revenue declines ahead of its Q3 earnings release.